FDA and Health Canada joint regulatory submission pilot
![](https://www.gmdnagency.org/wp-content/uploads/2023/07/Picture1-1.jpg)
15 January 2023
The U.S. Food and Drug Administration (FDA) is partnering with Health Canada to launch the joint eSTAR pilot. Requests for participating in the pilot are now open.
The pilot will test the use of a single regulatory submission to both the FDA and Health Canada.
The submission will need to include the GMDN Term for the product and therefore will be useful for demonstrating how the GMDN supports international harmonisation using an accurate generic name for the device type. Requests for participating in the pilot are now open.
More information is available from the FDA and Health Canada.
Health Canada
US FDA
www.fda.gov/medical-devices/how-study-and-market-your-device/health-canada-and-fda-estar-pilot
Recent Posts
- GMDN Agency and partners receive Innovate UK funding to research post-market medical device intelligence July 22, 2024
- New Software Developer joins GMDN Agency to improve digital offering July 17, 2024
- GMDN Agency and NHS Supply Chain announce collaboration agreement July 15, 2024
- WHO and GMDN Agency sign agreement in support of global harmonisation of medical device nomenclatures July 8, 2024
- GMDN FOCUS – June 2024 June 30, 2024